LE WE PMID CA
Pulmonary hypertension3003Pulmonale Hypertonie

Ambrisentan

Anemia (Sickle cell)

Angiogenesis

Asthma (occupational)

Blood vessels (Vasoconstriction)

BNP

Bosentan

Calcium (Capacitative transport)

Caveolin and caveoles

COPD

DHEA

Eisenmenger s syndrome

Endothelial dysfunction

Endothelin

Epoprostenol

Extrinsic compression of the left main coronary artery

Guanosine triphosphate cyclohydrolase

Guanylat cyclase

Heart (Coronary heart disease BASKET)

Heart (Echocardiography)

Heart (Imaging)

Heart (Inherited and congenital diseases in grown up patients)

Heart (Transplantation)

Heart failure (BASKET)

Heart failure (Right sided)

Hypoxic pulmonary vasoconstriction

Iloprost

Ion channel (Potassium)

Lung (Anatomy)

Lung (Fibrosis)

Lung (Infarct)

Lung (Transplantation)

Lung and bronchial system (Malformation)

Mitochondria (BASKET)

N methylsulfonyl 2 2 propynyloxy benzenehexanamide ttP450epoxygenase

Nitrates and prodrugs (Pharmacology)

Nitric oxide NO

Nitrite reductase

Oxygen (Hypoxia)

PDE phosphodiesterase

PDE5

Prostacyclin

Pulmonary embolism

Pulmonary emphysema

Pulmonary function testing

Pulmonary hypertension

Redox (BASKET)

Rho kinase

Sarcoidosis

Sclerodermia

Sildenafil

Sitaxsentan

Smooth muscle

Tadalafil

Thorax (Pain)

Treprostinil

TRPC6

TRPV4

2007  
1
Psychosocial aspects of pulmonary hypertension: a review.
[18071092] Psychosomatics 48(6): 467-75 (2007)
2007  
2
Pulmonary arterial hypertension: evaluation and management.
[17458400] South Med J 100(4): 393-9 (2007)
1993  
3
Pulmonary hypertension and cor pulmonale.
[8211354] South Med J 86(10): 2S7-10 (1993)
2008  
4
Mechanisms responsible for pulmonary hypertension.
[19187603] Chin Med J (Engl) 121(24): 2604-9 (2008)
2005  
5
Current treatment strategies for pulmonary arterial hypertension.
[16115293] J Intern Med 258(3): 199-215 (2005)
2002  
6
Primary pulmonary hypertension.
[12164370] Neth J Med 60(3): 133-9 (2002)
2007  
7
Diagnostic strategies for suspected pulmonary arterial hypertension: a primer for the internist.
[17941295] Cleve Clin J Med 74(10): 737-47 (2007)
2003  
8
Diagnosis and evaluation of pulmonary hypertension.
[12716138] Cleve Clin J Med 70 Suppl 1(-): S9-17 (2003)
2003  
9
Primary pulmonary hypertension: an overview of epidemiology and pathogenesis.
[12716137] Cleve Clin J Med 70 Suppl 1(-): S2-8 (2003)
2003  
10
Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists.
[12760982] Anesth Analg 96(6): 1603-16 (2003)
2003  
11
Pulmonary arterial hypertension: pathophysiology and anesthetic approach.
[14639158] Anesthesiology 99(6): 1415-32 (2003)
2007  
12
Chronic thromboembolic pulmonary hypertension (CTEPH).
[17699182] Heart 93(9): 1152-8 (2007)
2005  
13
Pulmonary artery dissection: an emerging cardiovascular complication in surviving patients with chronic pulmonary hypertension.
[15657218] Heart 91(2): 142-5 (2005)
2009  
14
Pulmonary hypertension in idiopathic pulmonary fibrosis: a review.
[19960783] Sarcoidosis Vasc Diffuse Lung Dis 26(1): 7-19 (2009)
2009  
15
The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?
[19808330] Circ Heart Fail 2(2): 145-50 (2009)
2010  
16
Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.
[20406243] Cardiovasc Ther 28(5): e65-71 (2010)
2010  
17
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.
[20479949] Vasc Health Risk Manag 6(-): 273-80 (2010)
2009  
18
RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.
[19707285] Vasc Health Risk Manag 5(-): 663-71 (2009)
2009  
19
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.
[19688101] Vasc Health Risk Manag 5(-): 607-19 (2009)
2009  
20
Treatment of pediatric pulmonary hypertension.
[19554091] Vasc Health Risk Manag 5(2): 509-24 (2009)
2009  
21
Inhaled iloprost for the control of pulmonary hypertension.
[19475782] Vasc Health Risk Manag 5(1): 465-74 (2009)
2009  
22
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
[19436672] Vasc Health Risk Manag 5(1): 325-31 (2009)
2008  
23
Treprostinil for pulmonary hypertension.
[18827901] Vasc Health Risk Manag 4(3): 507-13 (2008)
2007  
24
Review of bosentan in the management of pulmonary arterial hypertension.
[18200808] Vasc Health Risk Manag 3(6): 887-900 (2007)
2007  
25
A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
[17583185] Vasc Health Risk Manag 3(1): 151-7 (2007)
2007  
26
A review of pulmonary arterial hypertension: role of ambrisentan.
[17583171] Vasc Health Risk Manag 3(1): 11-22 (2007)
2007  
27
DHEA treatment of pulmonary hypertension: new insights into a complex mechanism.
[17466961] Cardiovasc Res 74(3): 337-8 (2007)
2004  
28
The endothelin system in pulmonary arterial hypertension.
[14736539] Cardiovasc Res 61(2): 227-37 (2004)
1999  
29
Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension.
[10690304] Cardiovasc Res 44(2): 274-82 (1999)
1997  
30
Pulmonary hypertension: updating a mysterious disease.
[9205539] Cardiovasc Res 34(2): 268-72 (1997)
2008  
31
Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.
[18536743] Br J Pharmacol 155(4): 444-54 (2008)
2008  
32
Pulmonary hypertension: therapeutic targets within the serotonin system.
[18536742] Br J Pharmacol 155(4): 455-62 (2008)
2000  
33
5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.
[10991906] Br J Pharmacol 131(2): 161-8 (2000)
2007  
34
2009  
35
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.
[20054445] Drug Des Devel Ther 3(): 269-87 (2009)
2009  
36
Ambrisentan for the treatment of pulmonary arterial hypertension.
[19920913] Drug Des Devel Ther 2(-): 265-80 (2009)
2009  
37
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
[19863849] Health Technol Assess 13(49): 1-320 (2009)
2010  
38
Optimising the management of pulmonary arterial hypertension patients: emergency treatments.
[20956193] Eur Respir Rev 19(117): 204-11 (2010)
2010  
39
Emergency treatments in pulmonary arterial hypertension: a place for algorithms and for education programmes.
[20956189] Eur Respir Rev 19(117): 171-2 (2010)
2007  
40
Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
[17409670] Tohoku J Exp Med 211(4): 309-20 (2007)
2000  
41
Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension.
[11015616] Physiol Rev 80(4): 1337-72 (2000)
2005  
42
Evaluation and management of the patient with pulmonary arterial hypertension.
[16103472] Ann Intern Med 143(4): 282-92 (2005)
2008  
43
The management of pulmonary hypertension in children.
[18381346] Arch Dis Child 93(7): 620-5 (2008)
2005  
44
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.
[16320330] Arthritis Rheum 52(12): 3792-800 (2005)
2002  
45
Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?
[12209501] Arthritis Rheum 46(8): 1997-2009 (2002)
1964  
46
PRIMARY PULMONARY HYPERTENSION: A REVIEW, AND REPORT OF FIVE CASES.
[14180523] Can Med Assoc J 91(-): 145-53 (1964)
2008  
47
Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.
[19059957] Chest 134(6): 1271-7 (2008)
2008  
48
ECG monitoring of treatment response in pulmonary arterial hypertension patients.
[18641107] Chest 134(6): 1250-7 (2008)
2008  
49
Estimation of mean pulmonary artery pressure: simpler than expected.
[18321898] Chest 133(3): 592-3 (2008)
2005  
50
Pulmonary arterial hypertension: the key role of echocardiography.
[15888866] Chest 127(5): 1836-43 (2005)
2004  
51
Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
[15249495] Chest 126(1 Suppl): 63S-71S (2004)
2004  
52
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
[15249494] Chest 126(1 Suppl): 35S-62S (2004)
2004  
53
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
[15249493] Chest 126(1 Suppl): 14S-34S (2004)
1984  
54
Pulmonary hypertensive diseases.
[6365477] Chest 85(3): 397-405 (1984)
1974  
55
A problem in pulmonary hypertension. 2. The final course and autopsy findings. A clinicopathologic conference from the Division of Pulmonary Diseases, Hahnemann Medical College and Hospital, Philadelphia.
[4810679] Chest 65(2): 192-7 (1974)
1971  
56
A reconsideration of the origins of pulmonary hypertension.
[5099816] Chest 59(1): 82-94 (1971)
2008  
57
Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?
[18614776] Clin J Am Soc Nephrol 3(5): 1232-7 (2008)
2008  
58
Biomarkers in pulmonary hypertension.
[18669790] Eur Respir J 32(2): 503-12 (2008)
2008  
59
Pulmonary hypertension in interstitial lung disease.
[18515559] Eur Respir J 31(6): 1357-67 (2008)
2008  
60
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
[18378784] Eur Respir J 31(4): 891-901 (2008)
2008  
61
Endothelin receptor antagonists in pulmonary arterial hypertension.
[18238950] Eur Respir J 31(2): 407-15 (2008)
2008  
62
Pulmonary hypertension: basic concepts and practical management.
[18238945] Eur Respir J 31(2): 236-7 (2008)
2006  
63
Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review.
[17074918] Eur Respir J 28(5): 999-1004 (2006)
2005  
64
Noninvasive assessment and monitoring of the pulmonary circulation.
[15802353] Eur Respir J 25(4): 758-66 (2005)
2004  
65
Chronic thromboembolic pulmonary hypertension.
[15083767] Eur Respir J 23(4): 637-48 (2004)
2003  
66
Pulmonary arterial hypertension in children.
[12570125] Eur Respir J 21(1): 155-76 (2003)
2002  
67
Pathobiology of pulmonary arterial hypertension.
[12503718] Eur Respir J 20(6): 1559-72 (2002)
2002  
68
Haemodynamic evaluation of pulmonary hypertension.
[12449189] Eur Respir J 20(5): 1314-31 (2002)
2002  
69
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.
[12412701] Eur Respir J 20(4): 1037-49 (2002)
2002  
70
Pulmonary hypertension in collagen vascular disease.
[11936539] Eur Respir J 19(3): 571-6 (2002)
1999  
71
Severe pulmonary hypertensive diseases: a perspective.
[10624750] Eur Respir J 14(6): 1246-50 (1999)
1996  
72
Medical management of primary pulmonary hypertension.
[8947091] Eur Respir J 9(11): 2401-9 (1996)
1995  
73
Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension.
[8666110] Eur Respir J 8(12): 2129-38 (1995)
1995  
74
More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited.
[8575567] Eur Respir J 8(9): 1445-9 (1995)
1994  
75
Medical treatment of pulmonary hypertension in chronic lung disease.
[8143814] Eur Respir J 7(1): 148-52 (1994)
2000  
76
Diagnosis and treatment of pulmonary hypertension associated with collagen diseases.
[10801140] Intern Med 39(4): 280-2 (2000)
2003  
77
Pulmonary arterial hypertension--the primary pulmonary hypertension syndromes.
[14509142] Isr Med Assoc J 5(4): 298-303 (2003)
2008  
78
Molecular pathogenesis of pulmonary arterial hypertension.
[18596905] J Clin Invest 118(7): 2372-9 (2008)
2009  
79
Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension.
[19567712] Mayo Clin Proc 84(7): 586-92 (2009)
2007  
80
Pulmonary hypertension in patients with interstitial lung diseases.
[17352370] Mayo Clin Proc 82(3): 342-50 (2007)
2001  
81
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
[11484688] N Engl J Med 345(5): 319-24 (2001)
2009  
82
Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation.
[19825167] Respir Res 10(-): 95 (2009)
2007  
83
Prognosis, screening, early detection and differentiation of arterial pulmonary hypertension.
[17629802] Swiss Med Wkly 137(23-24): 331-6 (2007)
2007  
84
Update on therapies for pulmonary hypertension.
[17370143] Swiss Med Wkly 137(5-6): 73-82 (2007)
2006  
85
Surgical treatment of chronic thromboembolic pulmonary hypertension.
[16947087] Swiss Med Wkly 136(31-32): 491-7 (2006)
2003  
86
1999  
87
Primary pulmonary hypertension.
[10567632] Thorax 54(12): 1107-18 (1999)
2008  
88
2004  
89
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.
[15194183] J Am Coll Cardiol 43(12 Suppl S): 81S-88S (2004)
2004  
90
Interventional and surgical modalities of treatment for pulmonary arterial hypertension.
[15194182] J Am Coll Cardiol 43(12 Suppl S): 73S-80S (2004)
2004  
91
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
[15194181] J Am Coll Cardiol 43(12 Suppl S): 68S-72S (2004)
2004  
92
Endothelin receptor antagonists in pulmonary arterial hypertension.
[15194180] J Am Coll Cardiol 43(12 Suppl S): 62S-67S (2004)
2004  
93
Prostanoid therapy for pulmonary arterial hypertension.
[15194179] J Am Coll Cardiol 43(12 Suppl S): 56S-61S (2004)
2004  
94
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.
[15194178] J Am Coll Cardiol 43(12 Suppl S): 48S-55S (2004)
2004  
95
Diagnosis and differential assessment of pulmonary arterial hypertension.
[15194177] J Am Coll Cardiol 43(12 Suppl S): 40S-47S (2004)
2004  
96
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
[15194176] J Am Coll Cardiol 43(12 Suppl S): 33S-39S (2004)
2004  
97
Pathologic assessment of vasculopathies in pulmonary hypertension.
[15194175] J Am Coll Cardiol 43(12 Suppl S): 25S-32S (2004)
2004  
98
Cellular and molecular pathobiology of pulmonary arterial hypertension.
[15194174] J Am Coll Cardiol 43(12 Suppl S): 13S-24S (2004)
2004  
99
Clinical classification of pulmonary hypertension.
[15194173] J Am Coll Cardiol 43(12 Suppl S): 5S-12S (2004)
2007  
100
Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs?
[17416597] Am J Physiol Heart Circ Physiol 293(1): H77-85 (2007)
2007  
101
The hyperproliferative endothelial cell phenotype in idiopathic pulmonary arterial hypertension.
[17601794] Am J Physiol Lung Cell Mol Physiol 293(3): L546-7 (2007)
2006  
102
Mediators and modulators of pulmonary arterial hypertension.
[16698850] Am J Physiol Lung Cell Mol Physiol 291(4): L547-58 (2006)
2008  
103
Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension.
[19015413] Circulation 118(21): 2190-9 (2008)
2008  
104
Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases.
[19015412] Circulation 118(21): 2120-1 (2008)
2008  
105
Emerging concepts and translational priorities in pulmonary arterial hypertension.
[18824655] Circulation 118(14): 1486-95 (2008)
2008  
106
Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.
[18779455] Circulation 118(11): 1195-201 (2008)
2006  
107
Pulmonary arterial hypertension.
[17000921] Circulation 114(13): 1417-31 (2006)
2006  
108
Chronic thromboembolic pulmonary hypertension.
[16636189] Circulation 113(16): 2011-20 (2006)
2009  
109
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
[19155250] Eur Heart J 30(4): 394-403 (2009)
2004  
110
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
[15589643] Eur Heart J 25(24): 2243-78 (2004)
2001  
111
Pulmonary arterial hypertension: new ideas and perspectives.
[11250981] Heart 85(4): 475-80 (2001)
1998  
112
Pulmonary thromboendarterectomy.
[9538301] Heart 79(2): 118-20 (1998)
1988  
113
Pulmonary hypertension complicating portal hypertension: findings on chest radiographs.
[3263020] AJR Am J Roentgenol 151(5): 909-14 (1988)
1987  
114
MR imaging of pulmonary arterial hypertension and pulmonary emboli.
[3495975] AJR Am J Roentgenol 149(1): 15-21 (1987)
2006  
115
Congenital and acquired pulmonary artery anomalies in the adult: radiologic overview.
[16549603] Radiographics 26(2): 349-71 (2006)
2000  
116
From the archives of the AFIP: pulmonary vasculature: hypertension and infarction.
[10715347] Radiographics 20(2): 491-524; quiz 530-1, 532 (2000)
1989  
117
Pulmonary arterial hypertension: a contemporary review.
[2678297] Radiographics 9(5): 905-27 (1989)
2010  
118
CT findings in diseases associated with pulmonary hypertension: a current review.
[21057119] Radiographics 30(7): 1753-77 (2010)
2007  
119
Pulmonary hypertension: accuracy of detection with left ventricular septal-to-free wall curvature ratio measured at cardiac MR.
[17392248] Radiology 243(1): 63-9 (2007)
2007  
120
Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging.
[17329691] Radiology 243(1): 70-9 (2007)
2010  
121
Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination.
[20093532] Radiology 254(2): 609-16 (2010)
2004  
122
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
[15308510] Ann Rheum Dis 63(9): 1009-14 (2004)
2008  
123
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.
[18083891] Am J Physiol Heart Circ Physiol 294(2): H570-8 (2008)
2008  
124
Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension.
[18790993] Am J Physiol Lung Cell Mol Physiol 295(6): L979-87 (2008)
2009  
125
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.
[19748998] Am J Physiol Lung Cell Mol Physiol 297(6): L1013-32 (2009)
2008  
126
Caveolin-1: a critical regulator of pulmonary vascular architecture and nitric oxide bioavailability in pulmonary hypertension.
[18296499] Am J Physiol Lung Cell Mol Physiol 294(5): L862-4 (2008)
2008  
127
Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice.
[18192592] Am J Physiol Lung Cell Mol Physiol 294(5): L865-73 (2008)
2007  
128
2010  
129
Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases.
[20585007] Circulation 122(2): 106-8 (2010)
2010  
130
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.
[20458021] Circulation 121(18): 2045-66 (2010)
2004  
131
Endothelial dysfunction in pulmonary hypertension.
[14734504] Circulation 109(2): 159-65 (2004)
2009  
132
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.
[19332472] Circulation 119(16): 2250-94 (2009)
2005  
133
Tetrahydrobiopterin in pulmonary hypertension: pulmonary hypertension in guanosine triphosphate-cyclohydrolase-deficient mice.
[15851611] Circulation 111(16): 2022-4 (2005)
2009  
134
Evidence for inflammatory signaling in idiopathic pulmonary artery hypertension: TRPC6 and nuclear factor-kappaB.
[19414653] Circulation 119(17): 2297-8 (2009)
2008  
135
Inoperable chronic thromboembolic pulmonary hypertension: treatable with medical therapy.
[18682450] Chest 134(2): 221-3 (2008)
2004  
136
Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines.
[15249496] Chest 126(1 Suppl): 72S-77S (2004)
2007  
137
Pulmonary hypertension: from an orphan disease to a public health problem.
[17699126] Chest 132(2): 365-7 (2007)
2007  
138
Pulmonary hypertension in idiopathic pulmonary fibrosis.
[17873194] Chest 132(3): 998-1006 (2007)
2007  
139
How do we explain unexplained pulmonary hypertension in the elderly?
[17218548] Chest 131(1): 5-6 (2007)
2009  
140
The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.
[19265089] Chest 135(3): 794-804 (2009)
2007  
141
Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.
[17356077] Chest 131(3): 657-63 (2007)
2007  
142
Angiogenesis in chronic lung disease.
[17356107] Chest 131(3): 874-9 (2007)
2007  
143
The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis.
[17356072] Chest 131(3): 641-3 (2007)
2007  
144
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
[17565025] Chest 131(6): 1917-28 (2007)
2009  
145
Endovascular therapy for left main compression syndrome. Case report and literature review.
[19497900] Chest 135(6): 1648-50 (2009)
2009  
146
Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need.
[19666759] Chest 136(2): 597-603 (2009)
2005  
147
Treatment for secondary pulmonary hypertension.
[16236830] Chest 128(4): 1897-8 (2005)
2005  
148
Pulmonary hypertension: cellular and molecular mechanisms.
[16373828] Chest 128(6 Suppl): 565S-571S (2005)
2006  
149
Thrombotic arteriopathy and anticoagulation in pulmonary hypertension.
[16899857] Chest 130(2): 545-52 (2006)
2011  
150
Pulmonary arterial hypertension associated with connective tissue disease and immunosuppressive therapy.
[21963571] Circ J 75(11): 2543-4 (2011)
2011  
151
Recent progress in the management of pulmonary hypertension.
[21747194] Circ J 75(8): 1801-10 (2011)
2010  
152
Dose-dependent reduction in pulmonary vascular resistance with epoprostenol in pulmonary arterial hypertension.
[20838003] Circ J 74(10): 2062-3 (2010)
2009  
153
Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension?
[19940372] Circ J 73(12): 2212-3 (2009)
2009  
154
Rho-kinase activation in patients with pulmonary arterial hypertension.
[19706987] Circ J 73(9): 1597-8 (2009)
2010  
155
Novel approaches to treat experimental pulmonary arterial hypertension: a review.
[20339474] J Biomed Biotechnol 2010(-): 702836 (2010)
2005  
156
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
[16055621] Thorax 60(12): 1025-30 (2005)
2005  
157
The endothelin system and its role in pulmonary arterial hypertension (PAH).
[15923241] Thorax 60(6): 443-4 (2005)
2005  
158
Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.
[15994270] Thorax 60(7): 605-9 (2005)
2010  
159
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.
[20504865] Eur Heart J 31(17): 2080-6 (2010)
2008  
160
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
[18562303] Eur Heart J 29(16): 1936-48 (2008)
2009  
161
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).
[19713419] Eur Heart J 30(20): 2493-537 (2009)
2009  
162
Developing new guidelines for the diagnosis and treatment of pulmonary hypertension.
[19842237] Eur Heart J 30(20): 2416-8 (2009)
2011  
163
New perspectives for the treatment of pulmonary hypertension.
[21175577] Br J Pharmacol 163(1): 125-40 (2011)
2008  
164
Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications.
[18084317] Br J Pharmacol 153 Suppl 1(-): S99-S111 (2008)
2006  
165
Pulmonary arterial hypertension (PAH) in connective tissue diseases.
[16987822] Rheumatology (Oxford) 45 Suppl 3(-): iii11-3 (2006)
2008  
166
Right ventricular function in scleroderma-related pulmonary hypertension.
[18784141] Rheumatology (Oxford) 47 Suppl 5(-): v42-3 (2008)
2008  
167
Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis.
[18784140] Rheumatology (Oxford) 47 Suppl 5(-): v39-41 (2008)
2008  
168
Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography.
[18784138] Rheumatology (Oxford) 47 Suppl 5(-): v33-5 (2008)
2006  
169
Primary pulmonary arterial hypertension and the systemic autoimmune diseases.
[16671366] Isr Med Assoc J 8(4): 277-9 (2006)
2002  
170
New treatments for pulmonary arterial hypertension.
[11991870] Am J Respir Crit Care Med 165(9): 1209-16 (2002)
2010  
171
2003  
172
Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway.
[12826592] Am J Respir Crit Care Med 168(1): 3-4 (2003)
2007  
173
Sickle cell disease-associated pulmonary hypertension: a coat of many colors.
[17545455] Am J Respir Crit Care Med 175(12): 1218-9 (2007)
2007  
174
Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.
[17255562] Am J Respir Crit Care Med 175(9): 875-80 (2007)
2003  
175
Autoimmune aspects of pulmonary hypertension in collagen vascular diseases.
[14714951] Intern Med 42(12): 1163-4 (2003)
2007  
176
Peripheral pulmonary artery aneurysms in patients with pulmonary artery hypertension.
[17603237] Intern Med 46(13): 979-84 (2007)
2008  
177
Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection.
[18212317] JAMA 299(3): 324-31 (2008)
2009  
178
Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
[19279988] Can J Cardiol 25(3): e63-8 (2009)
2007  
179
Pulmonary arterial hypertension: the mandatory role of the cardiologist.
[17629174] Hellenic J Cardiol 48(3): 123-6 (2007)
2005  
180
Recent advances in the treatment of pulmonary hypertension.
[15981551] Hellenic J Cardiol 46(3): 165-73 (2005)
2005  
181
Biochemical markers in the management of pulmonary hypertension.
[15729606] Swiss Med Wkly 135(3-4): 43-9 (2005)
2007  
182
The endothelium and genetics in pulmonary arterial hypertension.
[17705107] Swiss Med Wkly 137(31-32): 437-42 (2007)
2011  
183
Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension.
[21740775] Chin Med J (Engl) 124(11): 1672-7 (2011)
2011  
184
Pulmonary arterial hypertension: a comparison between children and adults.
[21357924] Eur Respir J 37(3): 665-77 (2011)
2010  
185
Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications.
[20123847] Eur Respir J 35(2): 418-25 (2010)
2010  
186
Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension.
[20044455] Eur Respir J 35(1): 6-8 (2010)
2009  
187
Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern.
[19336588] Eur Respir J 33(4): 717-21 (2009)
2005  
188
Autoimmunity and pulmonary hypertension: a perspective.
[16319344] Eur Respir J 26(6): 1110-8 (2005)
2005  
189
Pulmonary arterial hypertension: an autoimmune disease?
[16319325] Eur Respir J 26(6): 986-8 (2005)
2009  
190
Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension.
[19797668] Eur Respir J 34(4): 792-4 (2009)
2009  
191
The new definition of pulmonary hypertension.
[19797667] Eur Respir J 34(4): 790-1 (2009)
2009  
192
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
[19567606] Eur Respir J 34(1): 231-42 (2009)
2011  
193
The image of pulmonary hypertension.
[21755196] J Bras Pneumol 37(3): 283-4 (2011)
2010  
194
Diagnosis and treatment of pulmonary hypertension: an update.
[21225184] J Bras Pneumol 36(6): 795-811 (2010)
2007  
195
Sickle cell anemia-associated pulmonary arterial hypertension.
[18026658] J Bras Pneumol 33(5): 583-91 (2007)
2008  
196
Testing pulmonary vasoreactivity.
[19009218] J Bras Pneumol 34(10): 838-44 (2008)
2002  
197
The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?
[12430958] J Anat 201(4): 335-48 (2002)
2006  
198
Treatment of pulmonary arterial hypertension.
[17136291] J Pediatr (Rio J) 82(5 Suppl): S153-65 (2006)
2010  
199
Pulmonary hypertension in congenital shunts.
[20875358] Rev Esp Cardiol 63(10): 1179-93 (2010)
2010  
200
Current diagnostic and prognostic assessment of pulmonary Hypertension.
[20450852] Rev Esp Cardiol 63(5): 583-96 (2010)
2010  
201
Imaging techniques and the evaluation of the right heart and the pulmonary circulation.
[20109418] Rev Esp Cardiol 63(2): 209-23 (2010)
2010  
202
Prostacyclin therapy for pulmonary arterial hypertension.
[20844610] Tex Heart Inst J 37(4): 391-9 (2010)
2009  
203
Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem.
[19297247] Curr Opin Pharmacol 9(3): 287-96 (2009)
2007  
204
Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension.
[17363775] Am J Respir Cell Mol Biol 37(1): 31-7 (2007)
2005  
205
One hundred years of research in the pathogenesis of pulmonary hypertension.
[16234331] Am J Respir Cell Mol Biol 33(5): 425-31 (2005)
2010  
206
2008  
207
Pathogenic mechanisms of pulmonary arterial hypertension.
[17950310] J Mol Cell Cardiol 44(1): 14-30 (2008)
2010  
208
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
[20531962] Drug Des Devel Ther 4(-): 61-70 (2010)
2010  
209
Idiopathic pulmonary arterial hypertension.
[20427556] Dis Model Mech 3(5-6): 268-73 (2010)
2012  
210
Upregulation of osmo-mechanosensitive TRPV4 channel facilitates chronic hypoxia-induced myogenic tone and pulmonary hypertension.
[22207590] Am J Physiol Lung Cell Mol Physiol 302(6): L555-68 (2012)
2009  
211
A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation.
[20382348] Trends Cardiovasc Med 19(7): 238-42 (2009)
2005  
212
Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension.
[16247528] Can Respir J 12(6): 303-15 (2005)
2010  
213
Diagnosis and management of pulmonary hypertension in systemic sclerosis.
[20425528] Curr Rheumatol Rep 12(1): 8-18 (2010)
2011  
214
Recent progress in understanding pediatric pulmonary hypertension.
[21572384] Curr Opin Pediatr 23(3): 298-304 (2011)
2007  
215
Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension.
[17877662] Int J Clin Pract 61(10): 1756-65 (2007)
2008  
216
Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.
[21221188] Core Evid 2(4): 225-31 (2008)
2011  
217
Evaluation of pulmonary arterial hypertension: invasive or noninvasive?
[20473785] Int J Cardiovasc Imaging 27(7): 943-5 (2011)
2009  
218
Therapy for pulmonary arterial hypertension associated with systemic sclerosis.
[19667994] Curr Opin Rheumatol 21(6): 642-8 (2009)
2010  
219
Heart failure and pulmonary hypertension.
[20347789] Heart Fail Clin 6(2): 215-22 (2010)
2010  
220
Noninvasive assessment of pulmonary artery pressures: moving beyond tricuspid regurgitation velocities.
[20233861] Circ Cardiovasc Imaging 3(2): 132-3 (2010)
2010  
221
Perioperative management of pulmonary hypertension.
[20442537] Ann Card Anaesth 13(2): 89-91 (2010)
2008  
222
Current status of bosentan for treatment of pulmonary hypertension.
[18182753] Ann Card Anaesth 11(1): 6-14 (2008)
2010  
223
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.
[21701627] Drug Healthc Patient Saf 2(-): 151-61 (2010)
2009  
224
Cellular and molecular basis of pulmonary arterial hypertension.
[19555855] J Am Coll Cardiol 54(1 Suppl): S20-31 (2009)
2010  
225
Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension.
[21135983] Cardiovasc J Afr 21(6): 334-7 (2010)
2007  
226
Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy.
[17148943] Pharmacology 79(2): 65-75 (2007)
2011  
227
Recent trends in pulmonary arterial hypertension.
[21654985] Lung India 28(1): 39-48 (2011)
2011  
228
Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.
[21695644] Handb Exp Pharmacol -(204): 251-77 (2011)
2008  
229
Pulmonary hypertension: past, present and future.
[19561874] Ann Thorac Med 3(1): 1-4 (2008)
2009  
230
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.
[18950791] J Pediatr 154(3): 379-84, 384.e1-2 (2009)
2011  
231
Overview of current therapeutic approaches for pulmonary hypertension.
[22034603] Pulm Circ 1(2): 138-59 (2011)
2011  
232
Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography.
[22034604] Pulm Circ 1(2): 160-81 (2011)
2011  
233
Lung transplantation for pulmonary hypertension.
[22034605] Pulm Circ 1(2): 182-91 (2011)
2011  
234
Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension.
[22034607] Pulm Circ 1(2): 212-23 (2011)
2011  
235
Pulmonary hypertension related to left-sided cardiac pathology.
[21660234] Pulm Med 2011(-): 381787 (2011)
2008  
236
Nitric oxide and beyond: new insights and therapies for pulmonary hypertension.
[19057613] J Perinatol 28 Suppl 3(-): S67-71 (2008)
2010  
237
Initial Experience with Sildenafil, Bosentan, and Nitric Oxide for Pediatric Cardiomyopathy Patients with Elevated Pulmonary Vascular Resistance before and after Orthotopic Heart Transplantation.
[20224752] J Transplant 2010(-): 656984 (2010)
2007  
238
Pathology of pulmonary hypertension.
[17338926] Clin Chest Med 28(1): 23-42, vii (2007)
2008  
239
Pulmonary hypertension caused by sarcoidosis.
[18539244] Clin Chest Med 29(3): 549-63, x (2008)
2011  
240
Assessment of right ventricular structure and function in pulmonary hypertension.
[22073320] J Cardiovasc Ultrasound 19(3): 115-25 (2011)
2009  
241
Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension.
[19572023] Open Respir Med J 3(-): 85-9 (2009)
2010  
242
Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry.
[20549685] Catheter Cardiovasc Interv 76(6): 865-73 (2010)
2010  
243
New approaches to the treatment of pulmonary hypertension: from bench to bedside.
[20160533] Cardiol Rev 18(2): 76-84 (2010)
2009  
244
Integrated care and optimal management of pulmonary arterial hypertension.
[21197349] J Multidiscip Healthc 2(-): 67-78 (2009)
2010  
245
Prostacyclin in the intensive care setting.
[20216163] Pediatr Crit Care Med 11(2 Suppl): S41-5 (2010)
2010  
246
2007  
247
Pulmonary hypertension in sickle cell disease: relevance to children.
[17454785] Pediatr Hematol Oncol 24(3): 159-70 (2007)
2010  
248
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
[20170553] BMC Cardiovasc Disord 10(-): 9 (2010)
2007  
249
Pulmonary hypertension: clinical manifestations, classification and diagnosis.
[17663672] Int J Clin Pract Suppl -(156): 5-14 (2007)
2007  
250
Imaging of the heart in pulmonary hypertension.
[17663673] Int J Clin Pract Suppl -(156): 15-26 (2007)
2007  
251
Pulmonary hypertension and the serotonin hypothesis: where are we now?
[17663674] Int J Clin Pract Suppl -(156): 27-31 (2007)
2004  
252
Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation.
[15016901] News Physiol Sci 19(-): 44-50 (2004)
2010  
253
Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.
[20820751] J Mol Med (Berl) 88(10): 1011-20 (2010)
2010  
254
Reversible or irreversible remodeling in pulmonary arterial hypertension.
[20008280] Am J Respir Cell Mol Biol 43(6): 629-34 (2010)
2011  
255
Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.
[21177703] Cardiovasc Res 89(3): 542-52 (2011)
2010  
256
Management of severe pulmonary arterial hypertension.
[21119186] Eur Respir Rev 19(118): 279-87 (2010)
2010  
257
Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.
[21119185] Eur Respir Rev 19(118): 272-8 (2010)
2010  
258
Contemporary issues in pulmonary hypertension.
[21119184] Eur Respir Rev 19(118): 266-71 (2010)
PMC   
259
IL-13 receptor alpha2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension.
[23125252] Am J Physiol Lung Cell Mol Physiol 304(2):L112-24 (2013)
PMC   
260
Modern age pathology of pulmonary arterial hypertension.
[22679007] Am J Respir Crit Care Med 186(3):261-72 (2012)
PMC   
261
Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review.
[24400269] Front Pediatr 1():23 (2013)
PMC   
262
Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension.
[24470911] Infect Dis Rep 3(2):e14 (2011)
PMC   
263
A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure.
[23273594] J Card Fail 19(1):50-9 (2013)
PMC   
264
Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia.
[23328924] J Perinatol 33(7):553-7 (2013)
PMC   
265
A novel channelopathy in pulmonary arterial hypertension.
[23883380] N Engl J Med 369(4):351-61 (2013)
PMC   
266
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
[22511577] Pediatr Pulmonol 48(1):27-34 (2013)
PMC   
267
Pulmonary Arterial Hypertension in Patients with Primary Sjogren's Syndrome.
[24511390] Autoimmune Dis 2014():710401 (2014)
PMC   
268
Tezosentan increases nitric oxide signaling via enhanced hydrogen peroxide generation in lambs with surgically induced acute increases in pulmonary blood flow.
[22961736] J Cell Biochem 114(2):435-47 (2013)
PMC   
269
Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension.
[22688668] J Cell Physiol 228(2):322-9 (2013)
PMC   
270
CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit(+) cells in rats.
[24587052] PLoS One 9(2):e89810 (2014)
PMC   
271
Metabolomic heterogeneity of pulmonary arterial hypertension.
[24533144] PLoS One 9(2):e88727 (2014)
PMC   
272
Milrinone relaxes pulmonary veins in guinea pigs and humans.
[24498166] PLoS One 9(1):e87685 (2014)
PMC   
273
Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.
[24497961] PLoS One 9(1):e86636 (2014)
PMC   
274
Current challenges in pediatric pulmonary hypertension.
[24037630] Semin Respir Crit Care Med 34(5):627-44 (2013)
PMC   
275
Noninvasive assessment of right heart function and hemodynamics during exercise in patients with pulmonary arterial hypertension.
[23380750] South Med J 106(2):141-6 (2013)
PMC   
276
Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
[23590310] Am J Respir Cell Mol Biol 49(3):403-9 (2013)
PMC   
277
Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.
[23111998] Eur J Heart Fail 15(3):277-83 (2013)
PMC   
278
Vascular remodeling in pulmonary hypertension.
[23334338] J Mol Med (Berl) 91(3):297-309 (2013)
PMC   
279
FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.
[23247844] J Mol Med (Berl) 91(3):333-46 (2013)
PMC   
280
Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension.
[24507703] J Transl Med 12():39 (2014)
PMC   
281
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.
[23370913] Am J Respir Crit Care Med 187(6):648-57 (2013)
PMC   
282
Upregulated copper transporters in hypoxia-induced pulmonary hypertension.
[24614111] PLoS One 9(3):e90544 (2014)
PMC   
283
Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension.
[23594605] Respiration 85(5):355-64 (2013)
PMC   
284
PGC1alpha-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension.
[23449689] Am J Respir Crit Care Med 187(8):865-78 (2013)
PMC   
285
Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.
[23114789] Circulation 126(22):2601-11 (2012)
PMC   
286
Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension.
[24287663] Int J Clin Pharm 36(2):256-60 (2014)
PMC   
287
Clinical implications of haemoptysis in patients with pulmonary arterial hypertension.
[22943513] Int J Clin Pract Suppl (177):5-12 (2012)
PMC   
288
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
[23353807] J Control Release 167(2):189-99 (2013)
PMC   
289
Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension.
[24608803] Mol Cells 37(3):196-201 (2014)
PMC   
290
A new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies; pulmonary endarterectomy and percutaneous transluminal pulmonary angioplasty.
[24728482] PLoS One 9(4):e94587 (2014)
PMC   
291
Inflammatory cytokines in pulmonary hypertension.
[24739042] Respir Res 15():47 (2014)
PMC   
292
PPARgamma as a potential therapeutic target in pulmonary hypertension.
[20530063] Ther Adv Respir Dis 4(3):143-60 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Periphere Pulmonalarterienstenosen


  • Search PubMed and many other databases on the combined search terms

    GG: pulmonary hypertension
    GG: eisenmenger

  • Pulmonale Hypertonie

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia